Enveric Biosciences, Inc.

Enveric Biosciences, Inc. is a biotechnology company dedicated to the discovery and development of novel neuroplastogenic small-molecule therapeutics. The company's core mission is to address significant unmet needs in psychiatric and neurological disorders, including depression, anxiety, and addiction. Headquartered in Cambridge, Massachusetts, Enveric focuses on creating innovative treatments for mental health conditions.

Enveric's primary pipeline candidate is EB-003, a novel neuroplastogen designed to promote neuroplasticity without inducing hallucinogenic effects, targeting difficult-to-treat mental health disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD). The company also develops the EVM401 series, which includes novel phenylalkylamines, indolethylamines, and mescaline-derived compounds aimed at treating addiction and various neuropsychiatric conditions like opioid withdrawal and ADHD. These drug candidates are derived from its proprietary discovery platform, The Psybrary™, a robust library of novel molecules.

Joseph Tucker, Ph.D., serves as the CEO and Director of Enveric Biosciences. In September 2025, the company relocated its corporate headquarters to Cambridge, Massachusetts, to foster collaborations and enhance visibility within the life sciences sector. Enveric has recently made significant progress, including receiving a favorable FDA response in September 2025 regarding its pre-Investigational New Drug (IND) meeting for EB-003, streamlining its path toward an IND submission expected in early 2026. The company also completed key manufacturing milestones for EB-003 in October 2025 and secured new U.S. patents for its EVM301 and EVM401 series in late 2025 and early 2026. As an early-stage biotechnology firm, Enveric is currently pre-revenue, with its valuation tied to its intellectual property and pipeline development.